# US 2016/0256453 A1 · Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256453 A1
- Document ID: US20160256453A1
- Status: Published application
- Kind: A1
- Application number: 14/828,043
- Filed: 2015-08-17
- Published: 2016-09-08
- Earliest claimed: 2015-03-06
- Assignees: Develco Pharma Schweiz AG
- Applicants: Develco Pharma Schweiz AG
- Inventors: Helene Rey; Olaf Mundszinger; Isabelle Golfier; Silvia Jakob; Oliver Rusch
- Web page: https://patentgrep.com/patent/US20160256453A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a pharmaceutical composition comprising an opioid receptor antagonist, or a derivative or a pharmaceutically acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. The composition that is suitable for an administration period of at least twelve-hours for the treatment of severe opioid-induced constipation in patients receiving a daily dosage of opioid equivalent to at least 80 mg of morphine.

## Claims

### Claim 1

A method of a treating severe constipation comprising
administering a composition comprising an opioid receptor antagonist to a patient having severe opioid-induced constipation,
wherein the composition is prepared in a non-delayed, oral extended release formulation,
wherein the patient is receiving an opiate treatment with a dosage equivalent to at least 80 mg of morphine per day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the opioid receptor antagonist is a 11-receptor antagonist.

### Claim 3 (depends on 1)

The method of claim 1, wherein the opioid receptor antagonist is naloxone, methylnaltrexone, naltrexone, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises the opioid receptor antagonist, or the derivative or the pharmaceutically acceptable salt thereof, in a dose equivalent to 20 to 28 mg of naloxone.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition releases the opioid receptor antagonist independently of the ambient pH of the gastrointestinal tract, wherein the composition comprises a hydrophobic polymer.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the composition is a once-a-day formulation.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the composition is a twice-a-day formulation.

### Claim 9 (depends on 1)

The method of claim 1, wherein the opioid receptor antagonist is not naloxone.

### Claim 10 (depends on 1)

The method of claim 1, wherein the severe opioid-induced constipation is not caused by oxycodone.

### Claim 11

(canceled)
